docetaxel anhydrous has been researched along with Triple Negative Breast Neoplasms in 146 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 88 (60.27) | 24.3611 |
| 2020's | 58 (39.73) | 2.80 |
| Authors | Studies |
|---|---|
| Bahmanyar, S; Barnes, L; Boylan, JF; Calabrese, A; Canan, SS; Cashion, D; Chamberlain, PP; Chen, M; Delker, S; Deyanat-Yazdi, G; Elsner, J; Erdman, P; Harris, R; Huang, D; Katz, J; LeBrun, L; Leftheris, K; Miller, T; Moghaddam, MF; Nagy, M; Narla, RK; Pagarigan, B; Peng, X; Riggs, JR; Robinson, D; Tang, Y; Tehrani, L; Tran, T; Zhu, D | 1 |
| Bahmanyar, S; Boylan, JF; Cashion, D; Condroski, K; Elsner, J; Fenalti, G; Fultz, KE; Krishna Narla, R; Kulkarni, A; LeBrun, L; Leftheris, K; Nagy, M; Pagarigan, B; Peng, X; Riggs, JR; Robinson, D; Tehrani, L; Tran, T; Zhu, D | 1 |
| Cao, Y; Cheng, MY; Gao, HF; Ji, F; Li, J; Lin, Y; Liu, Z; Wang, K; Wu, ZY; Yang, CQ; Yang, M; Zhang, G; Zhang, L; Zhu, T | 1 |
| Guo, J; Wang, C; Wu, Z | 1 |
| Cheung, P; Chiu, JW; Kwok, G; Kwong, A; Leung, R; Li, B; Suen, D; Tsang, J; Wong, TT; Yau, T | 1 |
| Kong, CC; Liu, XD; Song, CY; Tian, X | 1 |
| Brugman, W; de Boo, LW; Hauptmann, M; Joensuu, H; Jóźwiak, K; Kluin, RJC; Kok, M; Lauttia, S; Lindman, H; Linn, SC; Nederlof, PM; Opdam, M; Schouten, PC; van Steenis, C | 1 |
| Chen, D; Lu, D; Ma, T; Yin, Y; Zhang, J | 1 |
| Cho, SG; Choi, YJ; Hwang, HH; Jeong, M; Jung, SE; Kim, YG; Ko, SG; Lee, K; Lee, SY; Yoon, JH | 1 |
| Crown, J; Duffy, MJ; O'Grady, S | 1 |
| Al-Zubaidi, Y; Bourget, K; Murray, M; Rahman, MK; Tam, S; Zhou, F | 1 |
| Lukong, KE; Mandapati, A | 1 |
| Li, H; Li, J; Liu, J; Liu, W; Mao, A; Pan, G; Rao, L; Sheng, X; Sun, X; Xie, X; Zhang, Q | 1 |
| Fan, M; Huang, G; Liu, Z; Ma, L; Xia, C; Xuan, X | 1 |
| Dong, M; Hong, C; Liu, S; Ma, S; Wang, A; Wang, D; Wang, J; Xia, J; Zhang, R; Zhang, S; Zhu, Y | 1 |
| Huang, Q; Li, S; Liao, M; Ma, H; Wu, M; Wu, X; Xi, H; Xia, Y; Zhang, Y | 1 |
| Asaoka, M; Ishikawa, T; Kawate, T; Miyahara, K; Muguruma, M; Teraoka, S | 1 |
| Jing, L; Lan, L; Mingxin, Z; Zhaofeng, Z | 1 |
| Ding, J; Kang, J; Li, H; Li, J; Liu, J; Liu, W; Lu, J; Mao, A; Pan, G; Zhang, Q | 1 |
| Deng, X; Liu, Q; Liu, W; Tan, D; Tang, Y; Tian, W; Wong, CW; Wu, L; Xie, J; Xie, X; Zhang, Y; Zheng, S; Zou, Y | 1 |
| Avitabile, C; Barbieri, A; Conte, C; Dal Poggetto, G; Laurienzo, P; Longobardi, G; Luciano, A; Palma, G; Pecoraro, A; Quaglia, F; Romanelli, A; Russo, A; Russo, G | 1 |
| Cui, X; Gao, Y; Jia, F; Li, M; Li, Y; Lu, J; Pan, Z; Wang, W; Wang, X; Wu, Y | 1 |
| Bae, ES; Byun, WS; Hong, J; Hong, S; Kim, Y; Lee, J; Lee, SB; Lee, SK; Lim, H | 1 |
| Feng, J; Li, B; Liu, J; Ni, S; Wang, D; Wang, L; Zhang, K | 1 |
| Byun, WS; Hong, I; Kim, A; Kim, HS; Kim, S; Kwon, Y; Lee, HS; Lee, SK; Song, J | 1 |
| Cheng, Y; Ji, Q; Liu, B; Liu, D; Liu, M; Yang, Q; Yang, Z; Zhang, B; Zhou, S | 1 |
| Cui, Z; Shi, B; Wang, T; Zhang, W | 1 |
| Armaly, AM; Aubé, J; He, L; Wei, L; Welch, DR; Wu, X; Xu, L; Zhang, Q; Zhang, Y; Zhong, C | 1 |
| Bliss, J; Cheang, MCU; Gazinska, P; Grigoriadis, A; Haider, S; Hoadley, KA; Kennedy, RD; Kernaghan, S; Kilburn, L; Loi, S; Parker, JS; Perou, CM; Pinder, SE; Quist, J; Roxanis, I; Salgado, R; Sipos, O; Tovey, H; Tutt, A | 1 |
| Ademuyiwa, FO; Anurag, M; Ellis, MJ; Holt, MV; Jaehnig, EJ; Kim, BJ; Lei, JT; Malovannaya, A; Rimawi, MF; Saltzman, AB; Wang, J; Young, MN | 1 |
| Jeong, J; Jin, MS; Jo, YH; Jung, H; Jung, Y; Kim, EG; Kim, HB; Kim, KM; Kim, SH; Kim, YD; Lee, J; Lee, YY; Ryu, HS; Seo, YR; Yi, EC | 1 |
| Abraham, DT; Backianathan, S; Balakrishnan, R; Chacko, RT; Cherian, AJ; George, TK; Georgy, JT; Joel, A; John, AO; Manipadam, MT; Patole, S; Paul, MJ; Ramnath, N; Rebekah, G; Sebastian, P; Sharma, P; Sigamani, E; Singh, A; Thumaty, DB | 1 |
| Almodlej, A; Arellano, L; Barbosa, S; Bouzas Mosquera, A; Cambón, A; Del Pino, P; Marcos, AV; Mosquera, VX; Pardo, A; Pelaz, B; Prieto, G; Taboada, P; Villar-Alvarez, E | 1 |
| Chen, L; Dong, C; Han, Y; Hu, X; Liang, S; Lin, Y; Liu, J; Lu, Y; Shi, S; Wang, C; Yao, T; Zhou, L | 1 |
| Armeson, K; Britten, C; Erlander, M; Ethier, S; Giordano, A; Kappler, C; Liu, Y; Park, Y; Reuben, J; Ridinger, M; Yeh, E | 1 |
| Bannister, AH; Bromma, K; Chithrani, DB; Chow, RL; Cicon, L; Howard, P; Monica, M; Schuemann, J; Sung, W | 1 |
| Sun, X; Wang, H; Yang, T; Yuan, Y | 1 |
| Ahmad, FJ; Akhter, S; Garg, N; Kumar Jain, G; Selvapandiyan, A; Zafar, S | 1 |
| Asleh, K; Brauer, HA; Chumsri, S; Joensuu, H; Lauttia, S; Lindman, H; Nielsen, TO; Sullivan, A; Thompson, EA | 1 |
| Fujita, T; Ishikawa, T; Narui, K; Oba, M; Sato, E; Teraoka, S; Yamada, A; Yamada, K | 1 |
| Abuhussein, O; Yang, J | 1 |
| Ishikawa, T; Kaise, H; Kawate, T; Miyahara, K; Miyazawa, K; Muguruma, M; Takano, N; Teraoka, S; Yamada, K | 1 |
| Bagger, SO; Brünner, N; Lund, TM; Nøhr-Nielsen, A; Stenvang, J | 1 |
| Abdelmaksoud, BA; Mohammed, A; Toam, MM | 1 |
| Eguchi, S; Iwata, T; Kanetaka, K; Kuba, S; Maeda, S; Matsumoto, M; Morita, M; Nagayasu, T; Otsubo, R; Sakimura, C; Sato, S; Yamanouchi, K; Yano, H | 1 |
| Cao, Y; Cui, S; Fan, Z; Fu, P; Guo, X; He, P; He, Q; Jiang, G; Jiang, J; Jin, F; Li, J; Li, X; Liu, P; Liu, Y; Ma, B; Mo, M; Pang, D; Qu, X; Rao, N; Ren, G; Shao, Z; Sheng, Y; Sun, Q; Tang, J; Wang, C; Wang, J; Wang, O; Wang, S; Wang, X; Xu, B; Yang, S; Yu, K; Yu, S; Zhang, G; Zhang, H; Zhang, J; Zhuang, Z | 1 |
| Abelha, TF; Alexander, C; Clarke, PA; Collins, HM; Gershkovich, P; Grabowska, AM; Gulfam, M; Heery, DM; Jerôme, C; Monteiro, CJ; Monteiro, PF; Pearce, AK; Travanut, A | 1 |
| Huang, T; Luo, S; Sun, X; Wu, J; Xu, H; Zhang, C | 1 |
| Chow, E; De Angelis, C; Jerzak, KJ; Monteiro, M; Rico, V; Shibahara, Y; Slodkowska, E; Tam, S; Zaki, P | 1 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Lambertini, M; Perachino, M; Poggio, F | 1 |
| Chen, SY; Cheng, HW; Chiang, CS; Hsu, CH; Lai, YH | 1 |
| Asaoka, M; Ishikawa, T; Kawate, T; Kuroda, M; Miyagi, Y; Miyahara, K; Muguruma, M; Okazaki, M; Teraoka, S; Ueda, A | 1 |
| Arai, K; Best, D; Brown, A; Dash, C; Eton, EO; Goldman, A; Goldman, D; Khiste, S; Kohandel, M; Mondal, J; Natarajan, SK; Pellowe, M; Rahman, M; Ramadurai, N; Saha, T; Sengupta, S; Shanthappa, B; Smalley, JL; Smalley, M; Thayakumar, A | 1 |
| Abdelhamid, MI; Abdelrahman, AE; Alnagar, AA; Elwan, A; Nawar, N | 1 |
| Fabian, KP; Fujii, R; Hodge, JW; Padget, MR; Schlom, J | 1 |
| Alvarez, E; Asensio, F; Bernat, R; Bueno, O; Cebollero, M; Del Monte-Millan, M; Echavarria, I; García-Saenz, JA; Gonzalez Del Val, R; Gonzalez-Haba, E; Herrero, B; Jerez, Y; Lizarraga, S; Lobato, N; Lopez-Tarruella, S; Marquez-Rodas, I; Martin, M; Massarrah, T; Moreno, F; Palomero, MI; Ramos-Medina, R; Rincon, P; Romero, P | 1 |
| Hong, HE; Jeon, YW; Kim, CH; Kim, OH; Kim, SJ; Shin, JS | 1 |
| Guo, S; Lei, J; Li, K; Liu, S; Peng, Y; Sun, L; Wang, Y; Yu, Y; Zhang, Y; Zong, B | 1 |
| Ademuyiwa, FO; Akintola-Ogunremi, O; Anurag, M; Bagegni, N; Basu, A; Bose, R; Chen, I; Church, SE; Clifton, K; Davis, J; Ellis, MJ; Ferrando-Martinez, S; Fisk, B; Frith, A; Gao, F; Gillanders, W; Griffith, M; Griffith, OL; Hagemann, IS; Hernandez-Aya, LF; Jeffers, G; Lee, BH; Luo, J; Ma, CX; Opyrchal, M; Peterson, LL; Rearden, TP; Richters, M; Rigden, CE; Rimawi, MF; Roshal, A; Skidmore, ZL; Suresh, R; Weilbaecher, K | 1 |
| Chui, SY; Emens, LA; Flores Avile, C; Lin, SW; Luhn, P; O'Shaughnessy, J; Russell, K; Schneeweiss, A; Wang, W | 1 |
| Chen, R; Chen, W; Feng, J; Hu, K; Liu, M; Ni, S | 1 |
| Climent, F; Esteller, M; Ferrer, I; Galván, P; Gómez-Miragaya, J; González-Suárez, E; Igea, A; Morilla, I; Muñoz, P; Nebreda, AR; Palafox, M; Paré, L; Pellegrini, P; Pérez-Montoyo, H; Pernas, S; Petit, A; Prat, A; Serra, V; Soler-Monso, MT; Urruticoechea, A; Vila, S; Yoldi, G | 1 |
| Liang, DS; Qi, XR; Su, HT; Wang, AT; Zhang, WJ; Zhong, HJ | 1 |
| Chao, TI; Chen, KF; Chen, MH; Chu, PY; Huang, CT; Huang, TT; Lau, KY; Lee, CH; Liu, CY; Shiau, CW; Su, JC; Tsai, WC; Tseng, LM; Wang, WL; Wu, CY; Yang, HP | 1 |
| Chanrion, M; Dewson, G; Geneste, O; Giner, G; Gong, JN; Gräsel, J; Herold, MJ; Huang, DCS; Lalaoui, N; Lessene, G; Li, X; Lindeman, GJ; Liu, K; Maragno, AL; Merino, D; Pal, B; Schneider, E; Segal, D; Serrano, A; Smyth, GK; Vaillant, F; Visvader, JE; Whittle, JR | 1 |
| Ding, T; Fan, Y; Gu, Z; Lin, G; Shi, Y; Wang, Q | 1 |
| Kai, M; Kubo, M; Nakamura, M; Yamada, M; Yamamoto, H | 1 |
| Gao, F; Gao, Q; Guo, Z; Wang, D; Wang, X; Wei, Y; Xie, W; Zhao, L | 1 |
| Bignon, L; Caron, O; Faivre, L; Fricker, JP; Gesta, P; Gladieff, L; Hamimi, A; Lasset, C; Lortholary, A; Mari, V; Mouret-Fourme, E; Nogues, C; Petit, T; Stoppa-Lyonnet, D; Velten, M | 1 |
| David, JM; Dominguez, C; McCampbell, KK; Palena, C | 1 |
| Chowdhury, N; Doddapaneni, R; Patel, K; Singh, M | 2 |
| Chen, C; Chen, Y; Jiang, X; Li, S; Shi, F; Wang, X; Xiong, H; Yan, T; Zhang, W; Zhu, Y | 1 |
| Li, Y; Meng, J; Meng, Q; Ran, W; Wang, J; Zhai, Y; Zhang, P | 1 |
| Almstedt, K; Battista, MJ; Fountzilas, G; Gerhold-Ay, A; Hasenburg, A; Heimes, AS; Hengstler, JG; Joensuu, H; Kalogeras, KT; Kellokumpu-Lehtinen, PL; Lebrecht, A; Sahin, U; Schmidt, M; Weyer-Elberich, V; Wirtz, RM | 1 |
| Li, S; Liang, Y; Ren, L; Tang, P; Wang, S; Wu, X; Zhang, T; Zhang, Y; Zhong, L | 1 |
| Bernöster, K; Häder, T; Herbener, P; Schönfeld, K; Schüttrumpf, J; Uherek, C; Zuber, C | 1 |
| Blohmer, JU; Costa, SD; Couch, FJ; Fasching, PA; Fehm, T; Gerber, B; Hart, SN; Hilfrich, J; Hu, C; Huober, J; Ingle, JN; Liedtke, C; Loibl, S; Moore, R; Müller, V; Nekljudova, V; Rack, B; Rezai, M; Rübner, M; Schem, C; Shimelis, H; Tesch, H; Untch, M; von Minckwitz, G; Wang, L; Weber, KE; Weinshilboum, RM | 1 |
| Burki, TK | 1 |
| Ferrari, M; Holder, AM; Liu, X; Mai, J; Mu, C; Shen, H; Shen, J; Wolfram, J; Wu, X; Xia, X; Zhang, D; Zhou, X | 1 |
| Turki, T; Wang, JTL; Wei, Z | 1 |
| Gaspar, BL; Katare, OP; Kesharwani, P; Khurana, RK; Kumar, R; Singh, B; Singh, KK; Welsby, G; Welsby, P | 1 |
| Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Mazzarello, S; Stober, C; Vandermeer, L | 1 |
| Bezares, S; Caballero, R; Cazet, AS; Chan, CL; Collot, R; Cooper, C; Cox, TR; Deng, N; Elsworth, BL; Harvey, K; Herrmann, D; Hui, MN; Johan, MZ; Lim, E; Martín, M; McFarland, A; Nair, R; O'Toole, S; Roden, D; Rojo, F; Ruiz-Borrego, M; Samuel, MS; Skhinas, JN; Swarbrick, A; Timpson, P; Trigo, JM; Watkins, DN; Wu, SZ; Yang, J | 1 |
| Amin, AL; Barnadas, A; Cortés, J; Fuentes-Rivera, H; García-Saenz, JA; Godwin, AK; Gómez, HL; González Del Val, R; González-Rivera, M; Heldstab, J; Jensen, RA; Jerez-Gilarranz, Y; Khan, QJ; Kimler, BF; Klemp, JR; Lehn, C; López-Tarruella, S; Mammen, JV; Márquez-Rodas, I; Martín, M; Massarrah, T; Monte-Millán, MD; Morales, DB; Moreno, F; O'Dea, AP; Palomero, MI; Pelaez-Lorenzo, B; Perou, CM; Picornell, AC; Prat, A; Sharma, P; Wagner, JL; Wang, YY | 1 |
| Choi, WS; Garcia, E; Godbout, R; Jain, S; Liu, RZ; Mackey, JR; Monckton, EA; Vo, TM | 1 |
| Gong, Y; Hao, S; Jiang, YZ; Jin, X; Ren, YX; Shao, ZM; Ye, FG | 1 |
| Blancafort, P; Clemons, TD; Dessauvagie, B; Evans, CW; Golden, E; Plani-Lam, JH; Redfern, AD; Sorolla, A; Swaminathan-Iyer, K; Wang, E | 1 |
| Arioka, H; Chishima, T; Doi, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Kosaka, Y; Kuranami, M; Mogaki, M; Morita, S; Narui, K; Nawata, S; Niikura, N; Oba, MS; Ogata, H; Ota, T; Saito, Y; Sasaki, T; Sengoku, N; Shimizu, D; Suto, A; Suzuki, Y; Tanabe, M; Tokuda, Y; Tsugawa, K; Yamada, A | 1 |
| Field, CJ; Goruk, S; Mazurak, V; Newell, M; Postovit, L | 1 |
| Futsuhara, K; Hata, S; Inoue, K; Kimizuka, K; Kojima, M; Kuroda, T; Nagai, SE; Saito, T; Sakurai, T; Yamada, H; Yamazaki, Y | 1 |
| Han, W; Kim, EK; Ko, E; Lee, KM; Noh, DY; Park, AK; Park, WY | 1 |
| Henry-Tillman, RS; Hutchins, LF; Klimberg, VS; Korourian, S; Makhoul, I; Siegel, ER; Westbrook, KC | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Buchholz, S; Engel, JB; Hohla, F; Ortmann, O; Rick, FG; Schally, AV; Seitz, S; Szalontay, L; Treszl, A; Zarandi, M | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Feng, SS; Kutty, RV | 1 |
| Cao, Y; Chen, X; Chen, Y; Li, X; Ni, D; Shen, K; Tang, J; Wei, Z; Wu, K; Xie, X; Ye, G; Zhang, C; Zheng, H | 1 |
| Fan, Y; Li, J; Liao, Y; Peng, L; Wan, Y | 1 |
| Akabane, T; Kaneko, N; Kita, A; Mori, M; Tabata, K; Yamanaka, K | 1 |
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Itoh, F; Maeda, I; Miyoshi, Y; Ohta, T; Oikawa, R; Tsuchiya, K; Tsugawa, K; Watanabe, Y; Wu, W | 1 |
| Balci, S; Cascione, L; Croce, CM; Fassan, M; Gasparini, P; Guler, G; Huebner, K; Irkkan, C; Lovat, F; Morrison, C; Shapiro, CL | 1 |
| Barron, SL; Batten, K; Cornelius, C; Fasciani, G; Jia, G; Shay, JW; Singel, SM; Wright, WE | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Hamburger, T; Nechushtan, H; Peretz, T; Salmon, AY; Stainberg, H; Vainer, G | 1 |
| Berger, F; de Cremoux, P; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hamy, AS; Hatt, M; Hindié, E; Marty, M; Merlet, P | 1 |
| Kalisch, A; Kern, P; Kimmig, R; Kolberg, HC; Kurbacher, C; Otterbach, F; Pott, D; Sikov, WM; von Minckwitz, G | 1 |
| Aboody, KS; Annala, AJ; Berlin, JM; Bhojane, S; Garcia, E; Kim, SU; Mooney, R; Smith-Powell, L; Weng, Y | 1 |
| Inoue, K; Sonoda, T; Tsubamoto, H | 1 |
| Arra, C; Barbieri, A; Bimonte, S; Conte, C; Luciano, A; Palma, G; Quaglia, F; Rea, D; Tirino, P; Ungaro, F | 1 |
| Kim, EK; Kim, MJ; Kim, SI; Moon, HJ; Park, BW; Park, S | 1 |
| Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocaña, A; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; Zaknoen, S | 1 |
| Barlaam, B; Barry, ST; Castriotta, L; Cosulich, S; Crafter, C; Cumberbatch, M; D'Cruz, C; Davies, BR; Dry, H; Ellston, R; Fitzek, M; Foster, E; Green, S; Hancox, U; Hanson, L; Harrington, EA; Lawson, M; Lenaghan, C; Ogilvie, D; Powell, S; Smith, PD; Trigwell, C; Ward, L; Wedge, SR | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M | 1 |
| Bansal, S; Ferrati, S; Grattoni, A; Hosali, S; Landis, M; Nicolov, E | 1 |
| Andò, S; Beyer, AR; Carstens, R; Covington, KR; Fuqua, SA; Gelsomino, L; Gu, G; Huffman, K; Rechoum, Y; Wang, J | 1 |
| Chia, SL; Feng, SS; Kutty, RV; Leong, DT; Muthu, MS; Setyawati, MI | 1 |
| Boon, U; Buijsman, RC; de Man, J; de Roos, JA; Janssen, A; Jonkers, J; Kops, GJ; Maia, AR; Medema, RH; Omerzu, M; Prinsen, MB; Song, JY; Sterrenburg, JG; Uitdehaag, JC; van Doornmalen, AM; Willemsen-Seegers, N; Zaman, GJ | 1 |
| Balacescu, L; Balacescu, O; Barbos, O; Berindan-Neagoe, I; Cojocneanu-Petric, R; Soritau, O; Tudoran, O; Visan, S | 1 |
| Kalisch, A; Kern, P; Kimmig, R; Kolberg, HC; Kurbacher, C; Pott, D; Pütter, C; Rezai, M; von Minckwitz, G | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| De Laurentiis, M; Mustacchi, G | 1 |
| Boakye, CHA; Chowdhury, N; Doddapaneni, R; Godugu, C; Patel, K; Singh, M | 1 |
| Montero, JC; Morís, F; Núñez, LE; Ocaña, A; Pandiella, A | 1 |
| Fox, MJ; Gibbs, P; Pickles, MD | 1 |
| Jo, U; Kang, J; Kim, I; Kim, YH; Lee, HJ; Park, JH; Park, JK; Park, KH; Seo, JH | 1 |
| Hu, Z; Ma, W; Tian, Z; Zang, L; Zhang, K; Zhao, P | 1 |
| A L-Abdulkarim, H; A L-Tweigeri, T; Abulkhair, O; Ajarim, D; Alawadi, S; AlSayed, A; Ashour, W; Ibrahim, M; Jaafar, H; Khalid, H | 1 |
| Abrial, C; Bahadoor, MR; Benmammar, KE; Bignon, YJ; Cayre, A; Chalabi, N; Chollet, P; Dauplat, MM; Durando, X; Jacquin, JP; Kullab, S; Kwiatkowski, F; Mouret-Reynier, MA; Nabholtz, JM; Penault-Llorca, F; Radosevic-Robin, N; Servent, V; Van Praagh, I | 1 |
| Ding, Y; Li, Y; Nie, G; Su, S; Wu, Y | 1 |
| Hu, YH; Li, XR; Liu, L; Zhang, J | 1 |
| Del Monte-Millán, M; Fuentes, H; García-Saenz, JA; Gómez, H; González-Rivera, M; Jerez, Y; Lobo, M; López-Tarruella, S; Márquez-Rodas, I; Martin, M; Massarrah, T; Moreno, F; Ocaña, I; Pérez-Carbornero, L; Picornell, A; Ramos-Medina, R; Santillán Garzón, S | 1 |
| He, W; Jin, HY; Liu, Q; Liu, YF; Wang, XF; Wei, ZX | 1 |
| Amin, AL; Barnadas, A; Bretel Morales, D; Connor, CS; Cortes, J; Del Monte-Millán, M; Fabian, CJ; Fuentes Rivera, H; García-Saenz, JA; Godwin, AK; Gómez, HL; González Del Val, R; Gonzalez-Rivera, M; Heldstab, J; Jensen, RA; Jerez-Gilarranz, Y; Khan, QJ; Kimler, BF; Klemp, JR; López-Tarruella, S; Mammen, JM; Márquez-Rodas, I; Martin, M; Massarrah, T; McGinness, MK; Moreno, F; Palomero, MI; Pelaez-Lorenzo, B; Perou, CM; Picornell, AC; Prat, A; Sharma, P; Wagner, JL; Ward, C | 1 |
| Bachelder, RE; Bowie, M; Cook, M; de Ridder, G; Groth, J; Kennedy, M; Kilibarda, K; Li, S; Lyes, M; Marcom, PK; McDonnell, DP; Nelson, ER; Parilla-Castellar, E; Payne, S; Peterson, BL; Pizzo, SV | 1 |
| Cao, W; Feng, T; Gu, X; Guo, Y; Li, J; Li, S; Liu, X; Liu, Y; Shen, W; Tsai, HI; Wu, F; Zhang, J; Zhang, L | 1 |
| Aubel, C; Bamdad, M; Bignon, YJ; El Guerrab, A; Penault-Llorca, F | 1 |
| Aftimos, P; Awada, A; Cesari, R; Curigliano, G; Dees, EC; Huang, B; Jiang, Y; Kern, KA; Locatelli, MA; LoRusso, PM; Pegram, MD; Shaik, MN | 1 |
| Bowerman, CJ; Byrne, JD; Chu, KS; Darr, DB; Deal, AM; DeSimone, JM; Keeler, AW; Luft, JC; Napier, ME; Perou, CM; Perry, JL; Schorzman, AN; Sharpless, NE; Sherwood, CA; Zamboni, WC | 1 |
| Abbasi, AZ; Cai, P; He, C; Henderson, JT; Li, J; Lin, L; Rauth, AM; Wu, XY; Zhang, T | 1 |
| Chen, KF; Chu, PY; Huang, CT; Huang, TT; Lau, KY; Lee, CH; Liu, CY; Shiau, CW; Su, JC; Tsai, WC; Tseng, LM; Wang, WL; Yang, HP | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Junnila, J; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Kosonen, S; Lahdenperä, O; Lindman, H; Nilsson, G; Nyandoto, P; Poikonen-Saksela, P; Tanner, M; Villman, K | 1 |
| Bai, S; Burnett, JP; Li, Y; Lim, G; Lim, R; McDermott, SP; Paholak, HJ; Shah, RB; Sun, D; Sun, L; Tsume, Y; Wicha, MS; Zhang, T | 1 |
| Cai, RG; Ding, XY; Fan, Y; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
2 review(s) available for docetaxel anhydrous and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Carcinoma, Ductal, Breast; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Dose Fractionation, Radiation; Female; Fibrocystic Breast Disease; Humans; Mastectomy; Sentinel Lymph Node Biopsy; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
The role of taxanes in triple-negative breast cancer: literature review.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
27 trial(s) available for docetaxel anhydrous and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Triple Negative Breast Neoplasms | 2022 |
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Homologous Recombination; Humans; Triple Negative Breast Neoplasms | 2022 |
Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Prognosis; Survival Rate; Triple Negative Breast Neoplasms | 2020 |
Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Prospective Studies; Time Factors; Triple Negative Breast Neoplasms | 2020 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Disease-Free Survival; Docetaxel; Female; Heterozygote; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4 Antigens; CD4-Positive T-Lymphocytes; Chemokine CXCL13; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Forkhead Transcription Factors; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Prognosis; Trastuzumab; Triple Negative Breast Neoplasms; Vinorelbine | 2018 |
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Cyclobutanes; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Mammary Glands, Human; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Organoplatinum Compounds; Remission Induction; Taxoids; Thrombocytopenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Genotype; Germ-Line Mutation; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2018 |
Responses to carboplatin in BRCA1/2-mutated breast cancer.
Topics: BRCA1 Protein; BRCA2 Protein; Carboplatin; Docetaxel; Female; Germ-Line Mutation; Humans; Prognosis; Treatment Outcome; Triple Negative Breast Neoplasms; United Kingdom | 2018 |
Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Doxorubicin; Endpoint Determination; Epirubicin; Feasibility Studies; Female; Fluorouracil; Guideline Adherence; Humans; Middle Aged; Paclitaxel; Pilot Projects; Random Allocation; Surveys and Questionnaires; Triple Negative Breast Neoplasms | 2018 |
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.
Topics: Adult; Aged; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Pyridines; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Mastectomy, Segmental; Middle Aged; Prognosis; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Black or African American; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Female; Humans; Lymph Nodes; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; White People | 2015 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Etoposide; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Odds Ratio; Pilot Projects; Survival Analysis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Docetaxel; ErbB Receptors; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cetuximab; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Taxoids; Triple Negative Breast Neoplasms | 2016 |
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tetrahydronaphthalenes; Triple Negative Breast Neoplasms; Valine; Vomiting | 2017 |
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Finland; Fluorouracil; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Sweden; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2017 |
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms | 2013 |
117 other study(ies) available for docetaxel anhydrous and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Female; Heterografts; Humans; Mice; Mitosis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; RNA Splicing; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2017 |
Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Docetaxel; Drug Design; Female; Mice, SCID; Microtubule-Associated Proteins; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Pyrroles; Rats; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Combinative treatment of Curdione and docetaxel triggers reactive oxygen species (ROS)-mediated intrinsic apoptosis of triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sesquiterpenes, Germacrane; Signal Transduction; Triple Negative Breast Neoplasms | 2021 |
Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Bufalin Induces Programmed Necroptosis in Triple-Negative Breast Cancer Drug-Resistant Cell Lines through RIP1/ROS-Mediated Pathway.
Topics: Antioxidants; Apoptosis; Bufanolides; Caspase 3; Cell Line; Cell Line, Tumor; Cysteine; Docetaxel; Doxorubicin; Fluorescein-5-isothiocyanate; Humans; Necroptosis; Propidium; Reactive Oxygen Species; Receptors, Tumor Necrosis Factor; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha | 2022 |
miR-1205/DNAJB1 reverses docetaxel chemoresistance in human triple negative breast carcinoma cells via regulation of mutp53/TAp63 signaling.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HSP40 Heat-Shock Proteins; Humans; MicroRNAs; Triple Negative Breast Neoplasms | 2022 |
SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Humans; Mice; Triple Negative Breast Neoplasms | 2022 |
Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2022 |
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms | 2022 |
Triple negative breast cancer: approved treatment options and their mechanisms of action.
Topics: Docetaxel; Doxorubicin; Epirubicin; Humans; Paclitaxel; Triple Negative Breast Neoplasms; United States | 2023 |
Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway.
Topics: Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; MicroRNAs; Signal Transduction; Survivin; Triple Negative Breast Neoplasms | 2022 |
Celastrol inhibits the migration and invasion and enhances the anti-cancer effects of docetaxel in human triple-negative breast cancer cells.
Topics: Cadherins; Cell Line, Tumor; Docetaxel; Humans; Pentacyclic Triterpenes; Triple Negative Breast Neoplasms | 2022 |
Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes.
Topics: Docetaxel; Ginsenosides; Glucose; Glucose Transporter Type 1; Humans; Liposomes; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Mice; Phosphatidylinositol 3-Kinases; Triple Negative Breast Neoplasms | 2022 |
β-Tubulin Isoforms Related to Docetaxel Sensitivity in 2D and 3D Cultured TNBC Cell Lines.
Topics: Cell Line; Cell Line, Tumor; Cisplatin; Docetaxel; Epirubicin; Humans; Protein Isoforms; Triple Negative Breast Neoplasms; Tubulin | 2022 |
METTL3/LINC00662/miR-186-5p feedback loop regulates docetaxel resistance in triple negative breast cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Feedback; Gene Expression Regulation, Neoplastic; Humans; Methyltransferases; MicroRNAs; Triple Negative Breast Neoplasms | 2022 |
Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel via targeting miR-200b-3p/Bcl-2 axis.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; MicroRNAs; RNA, Long Noncoding; Triple Negative Breast Neoplasms | 2022 |
Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Topics: Cell Death; Docetaxel; Humans; Prognosis; Transcriptome; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Mice; Nanoparticles; Peptides; Polymers; Triple Negative Breast Neoplasms | 2023 |
Self-assembled nanocomposites of carboxymethyl β-dextran/protamine sulfate for enhanced chemotherapeutic drug sensitivity of triple-negative breast cancer by autophagy inhibition via a ternary collaborative strategy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dextrans; Docetaxel; Drug Resistance; Humans; Mice; Nanocomposites; Triple Negative Breast Neoplasms | 2023 |
Design, Synthesis, and Biological Activity of Marinacarboline Analogues as STAT3 Pathway Inhibitors for Docetaxel-Resistant Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Mice; STAT3 Transcription Factor; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2023 |
Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235.
Topics: Cell Line, Tumor; Docetaxel; Humans; Imidazoles; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |
Synthesis and biological evaluation of atropisomeric tetrahydroisoquinolines overcoming docetaxel resistance in triple-negative human breast cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Docetaxel; Humans; Tetrahydroisoquinolines; Triple Negative Breast Neoplasms | 2023 |
Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression.
Topics: Bone Marrow Diseases; Bone Neoplasms; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Immunosuppression Therapy; Micelles; Osteolysis; Triple Negative Breast Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2023 |
The therapeutic and prognostic role of cuproptosis-related genes in triple negative breast cancer.
Topics: Apoptosis; Copper; Dasatinib; Docetaxel; Humans; Mutation; Prognosis; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |
Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; RNA-Binding Proteins; Triple Negative Breast Neoplasms | 2023 |
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; BRCA1 Protein; BRCA2 Protein; Carboplatin; DNA Damage; Docetaxel; Humans; Triple Negative Breast Neoplasms | 2023 |
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.
Topics: Antineoplastic Agents; Carrier Proteins; Docetaxel; Humans; Purines; Triple Negative Breast Neoplasms | 2023 |
Lateral interactions between CD276 and CD147 are essential for stemness in breast cancer: a novel insight from proximal proteome analysis.
Topics: B7 Antigens; Docetaxel; Humans; Membrane Proteins; Proteome; Proteomics; Transcription Factors; Triple Negative Breast Neoplasms | 2023 |
Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Platinum; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules.
Topics: Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Doxorubicin; Gold; Humans; Hyperthermia, Induced; Light; Nanocapsules; Nanotubes; Photochemotherapy; Phototherapy; Serum Albumin, Human; Triple Negative Breast Neoplasms | 2019 |
Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Survival; Copper; Docetaxel; Drug Carriers; Folic Acid; Humans; Immunotherapy; Lasers; Mice; Nanocomposites; Oligonucleotides; Phototherapy; Polyethyleneimine; Protoporphyrins; Reactive Oxygen Species; T-Lymphocytes, Cytotoxic; Triple Negative Breast Neoplasms | 2019 |
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Thiophenes; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Modulation of nanoparticle uptake, intracellular distribution, and retention with docetaxel to enhance radiotherapy.
Topics: Antineoplastic Agents; Biological Transport; Cell Survival; Docetaxel; Drug Synergism; Female; Gold; HeLa Cells; Humans; Metal Nanoparticles; Radiation-Sensitizing Agents; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2020 |
Identification of FOXE3 transcription factor as a potent oncogenic factor in triple-negative breast cancer.
Topics: Antineoplastic Agents; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Forkhead Transcription Factors; Humans; Oncogenes; Structure-Activity Relationship; Transcriptional Activation; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2020 |
Co-encapsulation of docetaxel and thymoquinone in mPEG-DSPE-vitamin E TPGS-lipid nanocapsules for breast cancer therapy: Formulation optimization and implications on cellular and in vivo toxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanocapsules; Phosphatidylethanolamines; Polyethylene Glycols; Triple Negative Breast Neoplasms; Vitamin E | 2020 |
Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology.
Topics: Antineoplastic Agents; Apoptosis; Breast; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Interactions; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lysophospholipids; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Sphingosine-1-Phosphate Receptors; Triple Negative Breast Neoplasms | 2020 |
Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines
Topics: Antineoplastic Agents; BRCA1 Protein; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Mutation; Triple Negative Breast Neoplasms | 2020 |
Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Interactions; Drug Synergism; Female; Humans; Triple Negative Breast Neoplasms | 2020 |
A Pilot Study of Extended Adjuvant Therapy with Metronomic Docetaxel for Patients with Operable Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Pilot Projects; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Optimal Tumor Reduction Rate and Modalities for Predicting pCR in Women With Breast Cancer.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Remission Induction; Trastuzumab; Triple Negative Breast Neoplasms; Tumor Burden; Ultrasonography | 2020 |
Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Humans; Micelles; Nanoparticles; Triple Negative Breast Neoplasms | 2020 |
Simultaneous delivery of anti-miRNA and docetaxel with supramolecular self-assembled "chitosome" for improving chemosensitivity of triple negative breast cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; MicroRNAs; Nanoparticles; Particle Size; Triple Negative Breast Neoplasms | 2021 |
Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Ovary; Paclitaxel; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Delayed-Action Preparations; Docetaxel; Drug Delivery Systems; Drug Stability; Female; Humans; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Polysaccharides; Triple Negative Breast Neoplasms | 2020 |
Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Inhibitory Concentration 50; Spheroids, Cellular; Triple Negative Breast Neoplasms | 2020 |
Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Breast Neoplasms; Cell Line, Tumor; Cholesterol; Docetaxel; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Killer Cells, Natural; Macrolides; Mice, Inbred BALB C; Molecular Targeted Therapy; Nanoparticles; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2020 |
Clinicopathological Features and Treatment Challenges in Triple Negative Breast Cancer Patients: A Retrospective Cohort Study.
Topics: Administration, Metronomic; Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Nitriles; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds; Triple Negative Breast Neoplasms; Young Adult | 2021 |
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
Topics: Animals; Antineoplastic Agents, Immunological; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Interleukin-15; Mice; Receptors, OX40; Recombinant Fusion Proteins; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Necrosis Factor Receptor Superfamily, Member 9; Vaccines, DNA; Xenograft Model Antitumor Assays | 2021 |
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Doxorubicin; Female; Humans; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Morpholines; Pyrimidines; Triple Negative Breast Neoplasms | 2022 |
HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.
Topics: Autophagy; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Rad51 Recombinase; Retrospective Studies; Triple Negative Breast Neoplasms; Tumor Burden | 2021 |
Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2021 |
Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Lipids; Mice; Micelles; Oligopeptides; Triple Negative Breast Neoplasms | 2021 |
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
Topics: Animals; Antineoplastic Agents; Cell Line; Cells, Cultured; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Integrin alpha6; Mice; Neoplastic Stem Cells; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Liberation; Female; Humans; Hyaluronan Receptors; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; Neuropilins; Particle Size; Polymers; Surface Properties; Taxoids; Triple Negative Breast Neoplasms | 2017 |
Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Phenyl Ethers; Phenylurea Compounds; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; STAT3 Transcription Factor; Taxoids; Transcription, Genetic; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Liposomes; Nanostructures; Prodrugs; Taxoids; Triple Negative Breast Neoplasms | 2017 |
[Efficacy of GC Therapy for the Patient of iTNBC with Resistance to TAC Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Taxoids; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
Injectable and Self-Healing Thermosensitive Magnetic Hydrogel for Asynchronous Control Release of Doxorubicin and Docetaxel to Treat Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Docetaxel; Doxorubicin; Humans; Hydrogels; Nanoparticles; Triple Negative Breast Neoplasms | 2017 |
Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Cell Line, Tumor; Cell Survival; Chemokines; Claudins; Docetaxel; Drug Therapy; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Interleukin-8; Mice; Myeloid-Derived Suppressor Cells; Signal Transduction; T-Lymphocytes; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2017 |
Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Mice; Noscapine; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer.
Topics: 3' Untranslated Regions; Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaempferols; Lymphatic Metastasis; MCF-7 Cells; Microfilament Proteins; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
Light-Activated Core-Shell Nanoparticles for Spatiotemporally Specific Treatment of Metastatic Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Chlorophyllides; Docetaxel; Female; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Photochemotherapy; Photosensitizing Agents; Porphyrins; RNA, Small Interfering; RNAi Therapeutics; Triple Negative Breast Neoplasms; Twist-Related Protein 1 | 2018 |
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Cell Line, Tumor; Docetaxel; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Nude; Paclitaxel; Syndecan-1; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer.
Topics: Animals; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Female; Gold; HSP27 Heat-Shock Proteins; Humans; Hyperthermia, Induced; Metal Nanoparticles; Mice; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Bortezomib; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Computational Biology; Databases, Factual; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Machine Learning; Multiple Myeloma; Triple Negative Breast Neoplasms | 2018 |
Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Clathrin; Docetaxel; Emulsions; Endocytosis; Fatty Acids, Unsaturated; Female; Humans; Lipids; Macrophages; Mice; Nanoparticles; Particle Size; Rats, Wistar; RAW 264.7 Cells; Static Electricity; Taxoids; Temperature; Time Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Mutation; NFI Transcription Factors; Signal Transduction; Transcription, Genetic; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2019 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2019 |
Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Docetaxel; Endocytosis; Female; Homeodomain Proteins; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; NIH 3T3 Cells; Oligopeptides; Polymers; Tissue Distribution; Triple Negative Breast Neoplasms | 2019 |
Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dietary Supplements; Disease Models, Animal; Docetaxel; Docosahexaenoic Acids; Drug Synergism; Female; Humans; Mice; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Silicates; Survival Rate; Titanium; Triple Negative Breast Neoplasms | 2020 |
Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Prognosis; Regression Analysis; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Female; Growth Hormone-Releasing Hormone; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Sermorelin; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Docetaxel; Humans; Mice; Micelles; Nanomedicine; Nanotechnology; Taxoids; Triple Negative Breast Neoplasms; Vitamin E | 2013 |
Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Naphthoquinones; Survivin; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Repair; Docetaxel; Female; Fluorouracil; Homologous Recombination; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Taxoids; Triple Negative Breast Neoplasms | 2013 |
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Keratin-5; Keratin-6; Methotrexate; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Risk Assessment; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Docetaxel; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; JNK Mitogen-Activated Protein Kinases; Kaplan-Meier Estimate; Lung Neoplasms; MCF-7 Cells; Microscopy, Fluorescence; Neoplasm Invasiveness; NF-kappa B; Prognosis; Receptor-Interacting Protein Serine-Threonine Kinase 2; RNA Interference; Signal Transduction; Taxoids; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Feasibility Studies; Female; Humans; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Female; Humans; Hydrogen-Ion Concentration; Injections, Intralesional; Kinetics; Mice; Mice, Inbred NOD; Mice, SCID; Nanomedicine; Nanoparticles; Neural Stem Cells; Polyethylene Glycols; Polymers; Polymethacrylic Acids; Solubility; Surface Properties; Taxoids; Technology, Pharmaceutical; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Inflammatory Breast Neoplasms; Itraconazole; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms | 2014 |
Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; beta-Cyclodextrins; Blood Proteins; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Docetaxel; Ethylene Glycols; Female; Humans; Mammary Neoplasms, Experimental; Mice, Nude; Nanoparticles; Polyesters; Powders; Taxoids; Triple Negative Breast Neoplasms; Tumor Burden | 2014 |
Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Contrast Media; Cyclophosphamide; Docetaxel; Female; Gadolinium DTPA; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2015 |
Therapeutic potential of ERK5 targeting in triple negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mitogen-Activated Protein Kinase 7; Molecular Targeted Therapy; Protein Kinase Inhibitors; Random Allocation; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2014 |
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Chromones; Docetaxel; Drug Synergism; Female; Humans; Male; Mice; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Neoadjuvant docetaxel/cyclophosphamide in triple-negative breast cancer: predictive value of class III-β tubulin and non-basal subtype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Taxoids; Triple Negative Breast Neoplasms; Tubulin | 2015 |
Docetaxel/2-Hydroxypropyl β -Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; beta-Cyclodextrins; Delayed-Action Preparations; Docetaxel; Drug Delivery Systems; Female; Humans; Mice; Mice, SCID; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Targeting thyroid hormone receptor beta in triple-negative breast cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; MCF-7 Cells; Prognosis; Signal Transduction; Taxoids; Thyroid Hormone Receptors beta; Triple Negative Breast Neoplasms | 2015 |
In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Breast; Cell Line, Tumor; Cetuximab; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Humans; Mice, SCID; Micelles; Polyethylene Glycols; Taxoids; Triple Negative Breast Neoplasms; Vitamin E | 2015 |
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Disease Models, Animal; Docetaxel; Drug Therapy, Combination; Female; Flow Cytometry; HeLa Cells; Humans; Immunoenzyme Techniques; Mice; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
Topics: Antibiotics, Antineoplastic; Cell Differentiation; Cell Self Renewal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplastic Stem Cells; Signal Transduction; Spheroids, Cellular; Taxoids; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2015 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Cyclosporine; Cytochrome P-450 CYP3A Inhibitors; Dioxolanes; Docetaxel; Drug Synergism; Female; Half-Life; Humans; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Taxoids; Triple Negative Breast Neoplasms | 2015 |
Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Docetaxel; Dose-Response Relationship, Drug; Female; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins; Phosphorylation; Plicamycin; Protein-Tyrosine Kinases; Signal Transduction; Taxoids; Time Factors; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Minkowski functionals: An MRI texture analysis tool for determination of the aggressiveness of breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Therapy; Epirubicin; Female; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Prognosis; Reproducibility of Results; Retrospective Studies; Software; Statistics, Nonparametric; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms.
Topics: Animals; Apoptosis; Caveolin 1; Cell Cycle Checkpoints; Docetaxel; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Receptors, Estrogen; Taxoids; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Filamins; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mammary Glands, Human; MAP Kinase Signaling System; Mice; RNA Interference; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Integration of photothermal therapy and synergistic chemotherapy by a porphyrin self-assembled micelle confers chemosensitivity in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Breast; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Carriers; Female; Humans; Hyperthermia, Induced; Mice, Inbred BALB C; Mice, Nude; Micelles; Photochemotherapy; Porphyrins; Taxoids; Triple Negative Breast Neoplasms | 2016 |
[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Gene Expression; Genes, erbB-1; Humans; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptor, ErbB-2; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
Topics: Adult; BRCA1 Protein; BRCA2 Protein; Carboplatin; Clinical Trials as Topic; Docetaxel; Female; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2016 |
Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Coumarins; Docetaxel; Drug Carriers; Enzyme Activation; Fluorescent Antibody Technique; Humans; JNK Mitogen-Activated Protein Kinases; Liposomes; Mice; Microtubules; Nanoparticles; Noscapine; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Polymerization; Staining and Labeling; Taxoids; Thiazoles; Triple Negative Breast Neoplasms; Tubulin; Xenograft Model Antitumor Assays | 2016 |
Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epigastric Arteries; Epirubicin; Female; Humans; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Case-Control Studies; Combined Modality Therapy; Docetaxel; Female; Filgrastim; Genes, BRCA1; Genes, BRCA2; Humans; Kansas; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Observational Studies as Topic; Polyethylene Glycols; Prospective Studies; Spain; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Cell Death; Cell Line, Tumor; Cell Membrane; Cell Movement; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Mice, Inbred NOD; Mice, SCID; Neoadjuvant Therapy; Neoplasm Invasiveness; Protein Precursors; Taxoids; Time Factors; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arctium; Asia, Eastern; Cell Line, Tumor; Cell Proliferation; DNA; Docetaxel; Drug Evaluation, Preclinical; Drug Synergism; Female; Fluorescent Antibody Technique; Furans; Humans; Hydrogen Bonding; Lignans; Mice, Nude; Molecular Docking Simulation; Plants, Medicinal; Protein Domains; Signal Transduction; STAT3 Transcription Factor; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Cetuximab; Cisplatin; DNA Damage; Docetaxel; ErbB Receptors; Female; Humans; Molecular Targeted Therapy; Mutation; Panitumumab; PTEN Phosphohydrolase; Taxoids; Triple Negative Breast Neoplasms | 2017 |
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Drug Resistance, Neoplasm; Female; Humans; Lactic Acid; Mice, Nude; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties; Taxoids; Triple Negative Breast Neoplasms | 2017 |
Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Mice, SCID; Nanoparticles; Polymers; Surface-Active Agents; Taxoids; Triple Negative Breast Neoplasms | 2017 |
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Taxoids; Triple Negative Breast Neoplasms | 2017 |
Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Isothiocyanates; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; NF-kappa B p52 Subunit; Paclitaxel; Phenotype; Signal Transduction; Sulfoxides; Taxoids; Time Factors; Transcription Factor RelA; Transcription, Genetic; Transfection; Triple Negative Breast Neoplasms; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |